Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
Marienid Flores-ColónDepartment of Biochemistry, University of Puerto Rico, Medical Sciences Campus, San Juan 00936, Puerto Rico.
Mariela Rivera-SerranoComprehensive Cancer Center, University of Puerto Rico, San Juan 00936, Puerto Rico.
Esther A Peterson-PegueroDepartment of Biology, University of Puerto Rico, Río Piedras Campus, San Juan 00921, Puerto Rico.
Pablo E Vivas-RiveraDepartment of Biology, University of Puerto Rico, Río Piedras Campus, San Juan 00921, Puerto Rico.
Fatima ValiyevaComprehensive Cancer Center, University of Puerto Rico, San Juan 00936, Puerto Rico.
Pablo E Vivas-MejíaDepartment of Biochemistry, University of Puerto Rico, Medical Sciences Campus, San Juan 00936, Puerto Rico.ORCID 0000-0002-2001-857X
Funding
Upgrade Laboratories Facilities at UPR-Rio PiedrasR25GM061151 · NIGMS · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI CARBALLEIRA, NESTOR MANUEL · 2001 to 2023
$32.5M
RISE Option III: MBRS RISE at the UPR Medical Sciences CampusR25GM061838 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI CADILLA, CARMEN LYDIA · 2000 to 2021
$25.5M
Promoting diversity in research careers in diabetes, digestive and kidney diseasesR25DK078381 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI MATTERS, GAIL L., REEVES, WILLIAM BRIAN · 2007 to 2024
$4.6M
Unraveling the Role of MMP3 in the Cisplatin Resistance of Ovarian CancerR16GM145558 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI VIVAS-MEJIA, PABLO ELIAS · 2022 to 2025
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Synthesis and Biological Evaluation of Herceptin-Conjugated Liposomes Loaded with Lipocalin-2 siRNA for the Treatment of Inflammatory Breast Cancer. · full record | Socratic